Last reviewed · How we verify
single infusion of Rituximab
single infusion of Rituximab is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 2 development. Also known as: single infusion of Rituximab 375 mg/m2.
At a glance
| Generic name | single infusion of Rituximab |
|---|---|
| Also known as | single infusion of Rituximab 375 mg/m2 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma (PHASE2)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
- Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies (PHASE1)
- Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma (PHASE2)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- single infusion of Rituximab CI brief — competitive landscape report
- single infusion of Rituximab updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about single infusion of Rituximab
What is single infusion of Rituximab?
single infusion of Rituximab is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes single infusion of Rituximab?
single infusion of Rituximab is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
Is single infusion of Rituximab also known as anything else?
single infusion of Rituximab is also known as single infusion of Rituximab 375 mg/m2.
What development phase is single infusion of Rituximab in?
single infusion of Rituximab is in Phase 2.
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Also known as: single infusion of Rituximab 375 mg/m2
- Compare: single infusion of Rituximab vs similar drugs
- Pricing: single infusion of Rituximab cost, discount & access